發，提早啟動「避險治療、邁向治癒」，千萬 不要發生遠端轉移讓疾病進展成晚期或轉移性 乳癌，屆時治療將更為棘手。 參考資料： 1.Stephen R D Johnston, Masakazu Toi, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial The Lancet Oncology. 2023; 24(1); P77-90 2.Matthew P. Goetz, Masakazu Toi, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer JOURNAL OF CLINICAL ONCOLOGY. 2017; 35(32); 3638-3646 3.George W. Sledge, Jr., Masakazu Toi, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 − Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy JOURNAL OF CLINICAL ONCOLOGY. 2017; 35(25); 2875-2884 4.Maura N. Dickler, Sara M. Tolaney, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer Clinical Cancer Research. 2017; 23(17); 5218-5224 捷癌寧 Verzenio 與芳香環酶抑制劑併用的疾病無惡化存活期高達 28.18 個月 捷癌寧 Verzenio 與 fulvestrant 併用的整體存活期達 45.8 個月、疾 病無惡化存活期達 16.9 個月 捷癌寧 Verzenio 與 fulvestrant 併用的整體存活期達 45.8 個月、疾 病無惡化存活期達 16.9 個月 後線單獨使用捷癌寧 Verzenio 治療的疾病無惡化存活期約 6 個月、 整體存活期 22 個月 恩主公醫訊 8 專題企 畫 粉紅十月 健康相繫
RkJQdWJsaXNoZXIy NDU0OQ==